Literature DB >> 33402473

Aberrant GLUT1 Expression Is Associated With Carcinogenesis and Progression of Liver Fluke-associated Cholangiocarcinoma.

Ubonrat Thamrongwaranggoon1,2, Sakkarn Sangkhamanon3, Wunchana Seubwai2,4, Paksiree Saranaruk1, Ubon Cha'on1, Sopit Wongkham5,2.   

Abstract

BACKGROUND/AIM: Glucose transporter 1 (GLUT1) has been demonstrated to be overexpressed in various cancer tissues and play a significant role on growth, metastasis, and apoptosis in cancer cells. This study aimed to reveal the clinical relevance of glucose transporter 1 (GLUT1) in carcinogenesis and progression on liver fluke-associated cholangiocarcinoma (CCA).
MATERIALS AND METHODS: Expression of GLUT1 in CCA tissues from patients, as well as from a liver fluke-induced CCA hamster model, was determined using immunohistochemistry. CCA cell lines were transfected with GLUT1 siRNA and the roles of GLUT1 on cell growth as well as migration and invasion were investigated by using a clonogenic assay and Boyden chamber assays, respectively.
RESULTS: GLUT1 was aberrantly expressed in hyperplastic/dysplastic bile ducts and CCA, but not in the normal bile ducts. High GLUT1 expression was significantly associated with non-papillary type, large tumor size, and short survival of patients. GLUT1 was expressed during cholangio-carcinogenesis and gradually increased with progression of histopathologic bile ducts. Silencing of GLUT1 expression significantly suppressed growth, migration, and invasion of CCA cell lines.
CONCLUSION: GLUT1 plays important roles in carcinogenesis and progression of liver fluke-associated CCA. Targeting GLUT1 may be a strategy for treatment of metastasis in liver fluke-associated CCA. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Glucose transporter 1; Opisthorchis viverrini; cholangiocarcinoma; poor prognosis; prognostic marker

Mesh:

Year:  2021        PMID: 33402473      PMCID: PMC7880799          DOI: 10.21873/invivo.12255

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  27 in total

1.  Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.

Authors:  Apinya Jusakul; Ioana Cutcutache; Chern Han Yong; Jing Quan Lim; Mi Ni Huang; Nisha Padmanabhan; Vishwa Nellore; Sarinya Kongpetch; Alvin Wei Tian Ng; Ley Moy Ng; Su Pin Choo; Swe Swe Myint; Raynoo Thanan; Sanjanaa Nagarajan; Weng Khong Lim; Cedric Chuan Young Ng; Arnoud Boot; Mo Liu; Choon Kiat Ong; Vikneswari Rajasegaran; Stefanus Lie; Alvin Soon Tiong Lim; Tse Hui Lim; Jing Tan; Jia Liang Loh; John R McPherson; Narong Khuntikeo; Vajaraphongsa Bhudhisawasdi; Puangrat Yongvanit; Sopit Wongkham; Yasushi Totoki; Hiromi Nakamura; Yasuhito Arai; Satoshi Yamasaki; Pierce Kah-Hoe Chow; Alexander Yaw Fui Chung; London Lucien Peng Jin Ooi; Kiat Hon Lim; Simona Dima; Dan G Duda; Irinel Popescu; Philippe Broet; Sen-Yung Hsieh; Ming-Chin Yu; Aldo Scarpa; Jiaming Lai; Di-Xian Luo; André Lopes Carvalho; André Luiz Vettore; Hyungjin Rhee; Young Nyun Park; Ludmil B Alexandrov; Raluca Gordân; Steven G Rozen; Tatsuhiro Shibata; Chawalit Pairojkul; Bin Tean Teh; Patrick Tan
Journal:  Cancer Discov       Date:  2017-06-30       Impact factor: 39.397

2.  Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach.

Authors:  Kenichi Komaya; Tomoki Ebata; Yukihiro Yokoyama; Tsuyoshi Igami; Gen Sugawara; Takashi Mizuno; Junpei Yamaguchi; Masato Nagino
Journal:  Surgery       Date:  2018-01-11       Impact factor: 3.982

3.  A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.

Authors:  Yi Liu; Yanyan Cao; Weihe Zhang; Stephen Bergmeier; Yanrong Qian; Huzoor Akbar; Robert Colvin; Juan Ding; Lingying Tong; Shiyong Wu; Jennifer Hines; Xiaozhuo Chen
Journal:  Mol Cancer Ther       Date:  2012-06-11       Impact factor: 6.261

4.  GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker.

Authors:  Kátia C Carvalho; Isabela W Cunha; Rafael M Rocha; Fernanda R Ayala; Mariana M Cajaíba; Maria D Begnami; Rafael S Vilela; Geise R Paiva; Rodrigo G Andrade; Fernando A Soares
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 5.  Glucose transporters in the 21st Century.

Authors:  Bernard Thorens; Mike Mueckler
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-12-15       Impact factor: 4.310

6.  Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD.

Authors:  Cen Zhang; Juan Liu; Rui Wu; Yingjian Liang; Meihua Lin; Jia Liu; Chang S Chan; Wenwei Hu; Zhaohui Feng
Journal:  Oncotarget       Date:  2014-07-30

Review 7.  Liver fluke induces cholangiocarcinoma.

Authors:  Banchob Sripa; Sasithorn Kaewkes; Paiboon Sithithaworn; Eimorn Mairiang; Thewarach Laha; Michael Smout; Chawalit Pairojkul; Vajaraphongsa Bhudhisawasdi; Smarn Tesana; Bandit Thinkamrop; Jeffrey M Bethony; Alex Loukas; Paul J Brindley
Journal:  PLoS Med       Date:  2007-07       Impact factor: 11.069

8.  Cholangiocarcinoma Trends, Incidence, and Relative Survival in Khon Kaen, Thailand From 1989 Through 2013: A Population-Based Cancer Registry Study.

Authors:  Supot Kamsa-Ard; Vor Luvira; Krittika Suwanrungruang; Siriporn Kamsa-Ard; Varisara Luvira; Chalongpon Santong; Tharatip Srisuk; Ake Pugkhem; Vajarabhongsa Bhudhisawasdi; Chawalit Pairojkul
Journal:  J Epidemiol       Date:  2018-08-04       Impact factor: 3.211

9.  Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway.

Authors:  Somsiri Indramanee; Kanlayanee Sawanyawisuth; Atit Silsirivanit; Paweena Dana; Chatchai Phoomak; Ryusho Kariya; Nathakan Klinhom-On; Supannika Sorin; Chaisiri Wongkham; Seiji Okada; Sopit Wongkham
Journal:  Sci Rep       Date:  2019-11-21       Impact factor: 4.379

10.  The Combination of MK-2206 and WZB117 Exerts a Synergistic Cytotoxic Effect Against Breast Cancer Cells.

Authors:  Yu-Liang Li; Hao-Cheng Weng; Jui-Ling Hsu; Shu-Wha Lin; Jih-Hwa Guh; Lih-Ching Hsu
Journal:  Front Pharmacol       Date:  2019-11-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.